Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenstrom Macroglobulinemia on and off Clinical Trials.

ABSTRACT: Ibrutinib is the first approved therapy for symptomatic patients with Waldenström macroglobulinemia (WM). The approval was based on a single, multicenter, phase II trial in previously treated WM patients. We sought to evaluate whether there were differences in clinical characteristics, response, and survival outcomes to ibrutinib monotherapy between WM patients treated on and off clinical trials. Treatment naïve and previously treated patients who received ibrutinib monotherapy at our institution and participated in two prospective studies (ON trial; n = 72) or a prospective database (OFF trial; n = 157) were included. The median times from WM diagnosis to ibrutinib initiation were 3.1 and 3.5 years for ON and OFF trial patients, respectively (p = 0.38). Similar rates of categorical respon

SUBMITTER: Castillo JJ 

PROVIDER: S-EPMC7306303 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature